Savara Inc Logo

Savara Inc

Clinical-stage biopharma developing inhaled therapies for rare respiratory diseases.

SVRA | US

Overview

Corporate Details

ISIN(s):
US8051111016
LEI:
Country:
United States of America
Address:
6836 BEE CAVE ROAD, 78746 AUSTIN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Savara Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). This therapy, with the conditionally accepted trade name MOLBREEVI, is in Phase 3 clinical development for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease. Savara's strategy is centered on addressing the significant unmet medical needs of patients with severe and life-threatening orphan respiratory conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Savara Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Savara Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Savara Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Flora Growth Corp. Logo
A diversified firm in pharma distribution, plant-based wellness, and digital assets.
United States of America FLGC
Foghorn Therapeutics Inc. Logo
Pioneering medicines targeting the chromatin regulatory system to treat genetically defined cancers.
United States of America FHTX
Formycon AG Logo
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
Germany FYB
Fortress Biotech, Inc. Logo
Acquires, develops, and commercializes drugs for oncology, gene therapy, and rare diseases.
United States of America FBIO
FRACTYL HEALTH, INC. Logo
Developing gut-targeted endoscopic and gene therapies for obesity and type 2 diabetes.
United States of America GUTS
Friulchem Logo
CDMO for animal health, providing vet pharma & supplement solutions for pets and livestock.
Italy FCM
Fuji Pharma Co.,Ltd. Logo
Specializes in hormone medicines for ob/gyn, injectables, and contract manufacturing.
Japan 4554
Fulcrum Therapeutics, Inc. Logo
Develops gene-modulating small molecule drugs for rare, genetically defined diseases.
United States of America FULC
Fuso Pharmaceutical Industries,Ltd. Logo
Manufactures essential pharmaceuticals like dialysis drugs, infusions, and injections for healthcare.
Japan 4538
FutureChem Co., Ltd. Logo
Develops radiopharmaceuticals & diagnostic agents for cancer, Alzheimer's, and Parkinson's disease.
South Korea 220100

Talk to a Data Expert

Have a question? We'll get back to you promptly.